Mr. Claudis Andre' Williams Jr., PA Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 700 24th St., Kenner Army Health Clinic, Ft. Lee, VA 23801 Phone: 804-734-6474 |
News Archive
Investigators from Children's Hospital Los Angeles and 37 other Children's Oncology Group hospitals in the U.S. and Canada have determined that sodium thiosulfate prevents cisplatin-induced hearing loss in children and adolescents with cancer.
Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.
California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.
Researchers from the UC San Diego, School of Medicine and colleagues have identified a new gene, ETS-1, that is linked to human congenital heart defects. The landmark study, recently published online in the journal of Human Molecular Genetics, provides important insights into some of the most prevalent forms of congenital heart defects in humans, including ventricular septal defects and potentially hypoplastic left heart syndrome, a uniformly fatal heart abnormality.
Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).
› Verified 5 days ago